Johnson & Johnson (JNJ) has been in the spotlight recently, and not just because of its iconic brand status. The company caught my attention due to a recent uptick in its sales outlook for 2026, projecting a midpoint revenue of $100.7 billion, which represents a growth of 6.7% to 7.1% according to Seeking Alpha. However, despite this seemingly positive news, JNJ's stock has been anything but stable.

So, what's going on with Johnson & Johnson? For one, the company is considering spinning out its hips-and-knees business, as reported by Seeking Alpha. This move could be a strategic decision to streamline operations and focus on more profitable segments. However, it's also a sign that JNJ is looking to offload parts of its business that may not align with its long-term growth strategy.

On the flip side, JNJ's stock recently took a hit, dropping 7% in one day. This was a reaction to mixed earnings news, where the company beat earnings expectations, yet the stock still stumbled, according to Motley Fool. This kind of market behavior is puzzling and suggests that investors might be wary of other underlying issues or are reacting to broader market pressures.

Given these developments, I'm left feeling uncertain about JNJ's immediate future. On one hand, the company's raised sales outlook is a positive indicator of potential growth. It shows confidence in its ability to generate revenue despite the challenges it faces. On the other hand, the decision to potentially spin off a part of its business and the recent stock drop signal that not everything is rosy. These actions could indicate internal challenges or shifts in strategic focus that aren't fully understood yet by the market.

The mixed sentiment around JNJ isn't just based on these recent events. A comparison with Pfizer, another healthcare giant, highlights some of the challenges JNJ faces. According to Motley Fool, while JNJ trades at a higher valuation with growing sales, Pfizer offers a hefty dividend yield. This comparison underscores the fact that while JNJ is growing, investors might see more immediate returns elsewhere.

What could go wrong for JNJ? Well, first, the potential spin-off of the hips-and-knees business could lead to short-term disruptions or costs that might not be immediately beneficial. Additionally, the market's reaction to their earnings beat but stock drop suggests there might be deeper concerns about JNJ's long-term strategy or market positioning. If these concerns aren't addressed, they could weigh heavily on the stock.

In conclusion, I'm uncertain about Johnson & Johnson's stock. The company has shown potential for growth with its increased sales outlook, but the market's reaction to its recent earnings and strategic shifts leaves me cautious. For now, I think it's best to keep a close eye on how these developments play out before making any definitive calls on JNJ's future.